Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients |
Gan, Gin Gin
(Department of Medicine, Faculty of Medicine, University Malaya)
Subramaniam, Rajaletchumy (Department of Medicine, Faculty of Medicine, University Malaya) Bee, Ping Chong (Department of Medicine, Faculty of Medicine, University Malaya) Chin, Edmund Fui Min (Department of Medicine, Faculty of Medicine, University Malaya) Abdul-Halim, Habibah (Department of Medicine, Faculty of Medicine, University Malaya) Tai, Mei Chee (Department of Medicine, Faculty of Medicine, University Malaya) |
1 | Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al ( 2007). The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res, 31, 1579-83. DOI ScienceOn |
2 | Sehn LH, Donalson J, Chhanabhai M, et al (2005), Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol, 23, 5027-33. DOI ScienceOn |
3 | Seiki R, Ohshima K, Nagafuji K, et al (2010). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 91, 258-66. DOI |
4 | Shia AKH, Gan GG, Jairaman S, Peh SC, et al (2005). High frequency of germinal centre derivation n diffuse large B cell lymphoma from Asian patients. J Clin Pathol, 58, 962-7. DOI ScienceOn |
5 | Teo MC, Soo KC (2013) Cancer trends and incidences in Singapore. Jpn J Clin Oncol, 43, 219-24. DOI ScienceOn |
6 | Chihara D, Ito H, Matsuda T, et al (2013). Differences in incidence and trends of hematological malignancies in Japan and United States. Br J Haematol, 164, 536-45. |
7 | Lenz G, Wright DH, Dave SS, et al (2007). Gene expression signatures predict overall survival in diffuse large B cell lymphoma treated with rituximab and CHOP-like chemotherapy. Blood, 110, 109. |
8 | Visco C, Tzankov A, Xu-Manoette ZY, et al (2013). Patients with diffuse large B cell lymphoma of germinal centre with BCL2 translocation have poor outcome; irrespective of MYC status: a report from an international DLBCL rituximab- CHOP consortium program study. Haematologica, 98, 255-63. DOI |
9 | Vose JM, Link BK, Grossbard ML, et al (2001). Phase II study of rituximab in combination of CHOP chemotherapy in patients with previously, untreated aggressive non-Hodgkin lymphoma. J Clin Oncol, 19, 387-97. |
10 | Ngo L, Hee SW, Lim LC, et al (2008). Prognostic factors in patients with diffuse large B cell lymphoma: before and after introduction of rituximab. Leukemia Lymphoma, 49, 462-9. DOI ScienceOn |
11 | Li JM, Wang L, Shen Y, et al (2007). Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol, 86, 639-45. DOI |
12 | Li Y, Yimamu M, Wang X, et al (2014). Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B-cell lymphoma cells with high Bcl-2 expression. Int J Hematol, 99, 79-86. DOI ScienceOn |
13 | Nishimori H, Matsua K, Maeda Y, et al (2009). The effect of adding rituximab to CHOP based therapy on clinical outcomes for Japanese patients with diffuse large b cell lymphoma: a propensity score matching analysis. Int J Hematol, 89, 326-31. DOI |
14 | Park YH, Lee JJ, Ryu MH, et al (2006). Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Int J Haem, 85, 257-2. |
15 | Coiffer B, Lepage E, Briere J, et al (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. New Eng J Med, 346, 235-42. DOI ScienceOn |
16 | Armitage JO (2012). My treatment approach to patients with Diffuse Large B cell Lymphoma. Mayo Clin Pro, 87, 161-71. DOI ScienceOn |
17 | Blay J, Gomez F, Sebban C, et al (1998). The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood, 92, 3562-8. |
18 | Castillo JJ, Sinclair N, Beltran BE, et al (2013). Similar outcomes in Asian and Western patients with diffuse large B cell lymphoma treated witn R-CHOP. Leukemia res, 37, 386-91. DOI ScienceOn |
19 | Feugier P, Van Hoof A, Sebban C, et al (2005). Long term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma, a study by European Groupe D'Estude des Lymphomes des L'Adulte (GELA). J Clin Oncol, 23, 4117-26. DOI ScienceOn |
20 | Fu K, Weisinburger DD, Choi WW, et al (2008). Addition of rituximab to standard chemotherapy improves the survival of germinal centre B-cell like and non germinal centre B-cell like subtypes of diffuse large B cell lymphoma. J Clin Oncol, 26, 4587-94. DOI ScienceOn |
21 | Huh J (2012). Epidemiologic overview of malignant lymphoma. Korean J Hematol, 47, 92-104. DOI ScienceOn |
22 | Intragumthornchai T, BunwarosateU, Siritanaratkul N, et al (2013). Inferior progression free survival for Thai patients with diffuse largeB-cell lymphoma treated under Universal Coverage Scheme, the impact of rituximab inaccessibility. Leuk Lymp, 54, 83-9. DOI ScienceOn |
23 | Pfreundschuh M, Trumper L, Ostenberg A, et al (2006). CHOP like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B cell lymphoma: a randomized controlled trial by the MabThera international trial (MInT) group. Lancet Oncol, 7, 379-91. DOI ScienceOn |
24 | Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. New Eng J Med, 346, 1937-47. DOI ScienceOn |